Guardant Health, Inc. Common Stock
GHStock
$155.00+238.86%52W
Market Cap$20.70B
P/E—
Div yield—
Beta1.63
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)38.78%
Price vs S&P 500 (4W)27.38%
VGM Score60.26
Market Capitalization$20.70B
Earnings Surprise History
Q1 26-0.45est. -0.48
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.29
4.29
4.30
4.34
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| VCYTVeracyte, Inc. | D | A | A | $59.22 |
| CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $71.96 |
About
Guardant Health is a liquid biopsy leader providing blood-based cancer tests for clinical detection and monitoring. The company's core franchises include Guardant360 for tumor genomic profiling, Reveal for molecular residual disease monitoring, and Shield for colorectal cancer screening. Guardant also offers regulatory consulting and clinical trial support services for the oncology research market.